UK-CAB funding

The administration costs for the UK-CAB are covered from the core budget of HIV i-Base. Some direct costs for UK-CAB meetings are covered by support from pharmaceutical companies (see details below).

From 2008-2011, an educational grant from The Monument Trust allowed us to employ a part-time administrator. Since 2011, this has been covered by HIV i-Base.

Funding by pharmaceutical companies

We ask pharmaceutical companies that have current HIV drugs to fund the direct costs for UK-CAB meetings.

This covers travel and accommodation for members coming from out of London, plus the cost of catering, for four meetings a year. This funding helps support the CAB as a national project. A list of supporting companies since the UK-CAB was established in 2002 and from the most recent two years is included below. [3]

The UK-CAB membership and Steering Group decides the content for the programme of meetings and agenda for these meetings. When the UK-CAB meeting with pharmaceutical companies about their current products and future research, the decisions for which companies to invite and the agenda for these meetings is made by the UK-CAB.

We similarly ask independent researchers to actively involved the UK-CAB in planning studies and ongoing research. We ask that community involvement in research be included in the budget of grant proposals so that some of the CAB work can be supported in this way by independent research.

Notes

  1. Directors and employees of pharmaceutical companies involved in research into HIV treatment and diagnostics, or employees of agencies providing PR, marketing and other professional services for these companies may not join the UK-CAB. We work closely with industry, but the UK-CAB is a community-based network, and it is important to respect this boundary.
  2. UK-CAB cannot provide any funding for people travelling from outside England, Wales, Scotland, Northern Ireland, Isle of Man or the Channel Islands.
  3. Since 2002, the UK-CAB has received support towards meeting costs from the following pharmaceutical companies: Abbott Laboratories, AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Gilead Sciences, GlaxoSmithKline (GSK), Janssen-Cilag, Koronis, Merck Sharp and Dohme (MSD), Roche Laboratories, Theratechnologies, Tibotec, Pfizer, ViiV Healthcare.
    Since April 2012, the UK-CAB has been supported by Abbott Laboratories, AbbVie, Bristol-Myers Squibb (BMS), Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme (MSD) and ViiV Healthcare.
    This funding is unconnected to the programme and content of meetings.
Published: January 29, 2016
Last edited: January 29, 2016